215 related articles for article (PubMed ID: 9214663)
1. Multidrug resistance in breast cancer--is the jury in yet?
Kaye SB
J Natl Cancer Inst; 1997 Jul; 89(13):902-3. PubMed ID: 9214663
[No Abstract] [Full Text] [Related]
2. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
Trock BJ; Leonessa F; Clarke R
J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of multidrug resistance gene expression.
Thorgeirsson SS; Gant TW; Silverman JA
Cancer Treat Res; 1994; 73():57-68. PubMed ID: 7710910
[No Abstract] [Full Text] [Related]
4. Multidrug resistance--a multiplex phenomenon.
Baldini N
Nat Med; 1997 Apr; 3(4):378-80. PubMed ID: 9095165
[No Abstract] [Full Text] [Related]
5. Transcriptional regulation of multidrug resistance in breast cancer.
Glazer RI; Rohlff C
Breast Cancer Res Treat; 1994; 31(2-3):263-71. PubMed ID: 7881104
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
Yakisich JS; Venkatadri R; Azad N; Iyer AKV
J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
[TBL] [Abstract][Full Text] [Related]
7. Role of gene amplification in drug resistance.
Schoenlein PV
Cancer Treat Res; 1994; 73():167-200. PubMed ID: 7710905
[No Abstract] [Full Text] [Related]
8. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Jaspers JE; Sol W; Kersbergen A; Schlicker A; Guyader C; Xu G; Wessels L; Borst P; Jonkers J; Rottenberg S
Cancer Res; 2015 Feb; 75(4):732-41. PubMed ID: 25511378
[TBL] [Abstract][Full Text] [Related]
9. Unanswered questions about multidrug resistance.
Beck WT
Cytotechnology; 1996; 19(3):177-9. PubMed ID: 8862003
[No Abstract] [Full Text] [Related]
10. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
11. The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.
Szakács G; Chen KG; Gottesman MM
Cancer Biol Ther; 2004 Apr; 3(4):382-4. PubMed ID: 14976423
[No Abstract] [Full Text] [Related]
12. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
13. Why does chemotherapy stop affecting the cells of ovarian and breast tumors?
Kalinina EV; Chernov NN
Future Oncol; 2018 May; 14(12):1137-1140. PubMed ID: 29629566
[No Abstract] [Full Text] [Related]
14. Enhancement of mdr1 gene expression by transforming growth factor-beta1 in the new adriamycin-resistant human leukemia cell line ME-F2/ADM.
Utsunomiya Y; Hasegawa H; Yanagisawa K; Fujita S
Leukemia; 1997 Jun; 11(6):894-5. PubMed ID: 9177449
[No Abstract] [Full Text] [Related]
15. Special Issue: New Approaches to Counteract Drug Resistance in Cancer.
Vasconcelos MH
Molecules; 2016 Dec; 22(1):. PubMed ID: 28025535
[TBL] [Abstract][Full Text] [Related]
16. In vitro models of multiple drug resistance.
Greenberger LM; Cohen D; Horwitz SB
Cancer Treat Res; 1994; 73():69-106. PubMed ID: 7710911
[No Abstract] [Full Text] [Related]
17. Reversing antibiotic resistance.
Hodgkinson R; Sharples D
Expert Opin Investig Drugs; 2002 Aug; 11(8):1023-32. PubMed ID: 12150699
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance-associated protein (MRP) in haematological malignancies.
Nooter K; Burger H; Stoter G
Leuk Lymphoma; 1996 Feb; 20(5-6):381-7. PubMed ID: 8833393
[TBL] [Abstract][Full Text] [Related]
19. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
20. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
